Cost and effectiveness. Cost-effectiveness analysis of different screening strategies: A - Incremental cost (×106 €) per life extended (LE); B - per year of life (YL); and C - per quality-adjusted life year (QALY). Empty figures correspond to annual strategies and full figures to biennial. Screening start age: 40 (big), 45 (medium) and 50 (small). Screening end age: 69 (circle), 70 (diamond), 74 (triangle), and 79 (square). The line joins the dominant scenarios. D - Cost for all strategies by phase: detection (pink), initial treatment (green), follow-up (blue), and advanced care (yellow).
Carles et al. BMC Cancer 2011 11:192 doi:10.1186/1471-2407-11-192